WO1998011244A2
(en)
|
1996-09-11 |
1998-03-19 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Aav4 vector and uses thereof
|
AU762220B2
(en)
|
1998-05-28 |
2003-06-19 |
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The |
AAV5 vector and uses thereof
|
US7226739B2
(en)
|
2001-03-02 |
2007-06-05 |
Isis Pharmaceuticals, Inc |
Methods for rapid detection and identification of bioagents in epidemiological and forensic investigations
|
US20040121335A1
(en)
|
2002-12-06 |
2004-06-24 |
Ecker David J. |
Methods for rapid detection and identification of bioagents associated with host versus graft and graft versus host rejections
|
US7666588B2
(en)
|
2001-03-02 |
2010-02-23 |
Ibis Biosciences, Inc. |
Methods for rapid forensic analysis of mitochondrial DNA and characterization of mitochondrial DNA heteroplasmy
|
US7718354B2
(en)
|
2001-03-02 |
2010-05-18 |
Ibis Biosciences, Inc. |
Methods for rapid identification of pathogens in humans and animals
|
US20030027135A1
(en)
|
2001-03-02 |
2003-02-06 |
Ecker David J. |
Method for rapid detection and identification of bioagents
|
US8073627B2
(en)
|
2001-06-26 |
2011-12-06 |
Ibis Biosciences, Inc. |
System for indentification of pathogens
|
US7217510B2
(en)
|
2001-06-26 |
2007-05-15 |
Isis Pharmaceuticals, Inc. |
Methods for providing bacterial bioagent characterizing information
|
IL161827A0
(en)
|
2001-11-13 |
2005-11-20 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novelsequences identified thereby
|
JP4810062B2
(ja)
*
|
2001-12-17 |
2011-11-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
アデノ随伴ウイルス(aav)血清型8の配列
|
ES2664505T3
(es)
*
|
2001-12-17 |
2018-04-19 |
The Trustees Of The University Of Pennsylvania |
Secuencias de serotipo 9 de virus adeno-asociado (AAV), vectores que las contienen, y usos de las mismas
|
WO2003093460A1
(en)
*
|
2002-04-29 |
2003-11-13 |
The Trustees Of The University Of Pennsylvania |
Method for direct rescue and amplification of integrated viruses from cellular dna of tissues
|
US7419817B2
(en)
|
2002-05-17 |
2008-09-02 |
The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. |
Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography
|
WO2004020600A2
(en)
*
|
2002-08-28 |
2004-03-11 |
University Of Florida |
Modified aav
|
JP2006516193A
(ja)
|
2002-12-06 |
2006-06-29 |
アイシス・ファーマシューティカルス・インコーポレーテッド |
ヒトおよび動物における病原体の迅速な同定方法
|
US8046171B2
(en)
|
2003-04-18 |
2011-10-25 |
Ibis Biosciences, Inc. |
Methods and apparatus for genetic evaluation
|
US8057993B2
(en)
|
2003-04-26 |
2011-11-15 |
Ibis Biosciences, Inc. |
Methods for identification of coronaviruses
|
US8158354B2
(en)
|
2003-05-13 |
2012-04-17 |
Ibis Biosciences, Inc. |
Methods for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
|
US7964343B2
(en)
|
2003-05-13 |
2011-06-21 |
Ibis Biosciences, Inc. |
Method for rapid purification of nucleic acids for subsequent analysis by mass spectrometry by solution capture
|
WO2005017101A2
(en)
|
2003-05-19 |
2005-02-24 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH |
Avian adenoassociated virus (aaav) and uses thereof
|
PL2657248T3
(pl)
*
|
2003-06-19 |
2017-09-29 |
Genzyme Corporation |
Wiriony AAV o zmniejszonej immunoreaktywności i ich zastosowanie
|
US9441244B2
(en)
|
2003-06-30 |
2016-09-13 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
US9233131B2
(en)
*
|
2003-06-30 |
2016-01-12 |
The Regents Of The University Of California |
Mutant adeno-associated virus virions and methods of use thereof
|
AU2010201278B2
(en)
*
|
2003-09-01 |
2012-11-15 |
Academisch Medisch Centrum |
AAV vectors for in vivo gene therapy of rheumatoid arthritis
|
US8529885B2
(en)
*
|
2003-09-01 |
2013-09-10 |
Academisch Medisch Centrum |
AAV vectors for in vivo gene therapy of rheumatoid arthritis
|
US20120122101A1
(en)
|
2003-09-11 |
2012-05-17 |
Rangarajan Sampath |
Compositions for use in identification of bacteria
|
US8546082B2
(en)
|
2003-09-11 |
2013-10-01 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
US8097416B2
(en)
|
2003-09-11 |
2012-01-17 |
Ibis Biosciences, Inc. |
Methods for identification of sepsis-causing bacteria
|
PL2292780T3
(pl)
|
2003-09-30 |
2018-05-30 |
The Trustees Of The University Of Pennsylvania |
Klady wirusów związanych z adenowirusami (AAV), sekwencje, wektory je zawierające i ich zastosowania
|
AU2011250849B2
(en)
*
|
2003-09-30 |
2013-09-12 |
The Trustees Of The University Of Pennsylvania |
Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor
|
WO2005056807A2
(en)
*
|
2003-12-04 |
2005-06-23 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health |
Bovine adeno-associated viral (baav) vector and uses thereof
|
US7666592B2
(en)
|
2004-02-18 |
2010-02-23 |
Ibis Biosciences, Inc. |
Methods for concurrent identification and quantification of an unknown bioagent
|
US8119336B2
(en)
|
2004-03-03 |
2012-02-21 |
Ibis Biosciences, Inc. |
Compositions for use in identification of alphaviruses
|
JP2007535550A
(ja)
*
|
2004-04-28 |
2007-12-06 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
アデノウイルスおよびアデノ随伴ウイルス媒介投与を介する免疫原性分子の連続的な送達
|
JP2007535541A
(ja)
*
|
2004-04-28 |
2007-12-06 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
E4欠失アデノウイルス初回免疫およびe1欠失アデノウイルス追加免疫を用いる免疫化方式
|
JP4810533B2
(ja)
|
2004-05-24 |
2011-11-09 |
アイビス バイオサイエンシズ インコーポレイティッド |
ディジタルスレショルド化による選択的イオン濾過作用を用いた質量分光測定法
|
US20050266411A1
(en)
|
2004-05-25 |
2005-12-01 |
Hofstadler Steven A |
Methods for rapid forensic analysis of mitochondrial DNA
|
US7811753B2
(en)
|
2004-07-14 |
2010-10-12 |
Ibis Biosciences, Inc. |
Methods for repairing degraded DNA
|
EP1771571A2
(de)
*
|
2004-07-30 |
2007-04-11 |
Targeted Genetics Corporation |
Impfungsmethode basierend auf rekombinant aav
|
US7309589B2
(en)
*
|
2004-08-20 |
2007-12-18 |
Vironix Llc |
Sensitive detection of bacteria by improved nested polymerase chain reaction targeting the 16S ribosomal RNA gene and identification of bacterial species by amplicon sequencing
|
WO2006135400A2
(en)
|
2004-08-24 |
2006-12-21 |
Isis Pharmaceuticals, Inc. |
Methods for rapid identification of recombinant organisms
|
MX2007003922A
(es)
*
|
2004-10-05 |
2007-06-07 |
Merz Pharma Gmbh & Co Kgaa |
Nuevas propenonas ciclicas y aciclicas para tratar trastornos del sistema nervioso central.
|
US8084207B2
(en)
|
2005-03-03 |
2011-12-27 |
Ibis Bioscience, Inc. |
Compositions for use in identification of papillomavirus
|
CA2600184A1
(en)
|
2005-03-03 |
2006-09-08 |
Isis Pharmaceuticals, Inc. |
Compositions for use in identification of adventitious viruses
|
DE23193606T1
(de)
|
2005-04-07 |
2024-02-15 |
The Trustees Of The University Of Pennsylvania |
Verfahren zur erhöhung der funktion eines aav-vektors
|
US8283151B2
(en)
|
2005-04-29 |
2012-10-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
|
US8026084B2
(en)
|
2005-07-21 |
2011-09-27 |
Ibis Biosciences, Inc. |
Methods for rapid identification and quantitation of nucleic acid variants
|
JP2009519010A
(ja)
*
|
2005-11-28 |
2009-05-14 |
アイビス バイオサイエンシズ インコーポレイティッド |
外来混入ウイルスの同定に使用するための組成物
|
US7588772B2
(en)
|
2006-03-30 |
2009-09-15 |
Board Of Trustees Of The Leland Stamford Junior University |
AAV capsid library and AAV capsid proteins
|
WO2007127264A2
(en)
|
2006-04-28 |
2007-11-08 |
The Trustees Of The University Of Pennsylvania |
Scalable production method for aav
|
JP5623740B2
(ja)
*
|
2006-07-25 |
2014-11-12 |
セラドン・コーポレーション |
遺伝子治療用アデノ随伴ウイルスベクターの長期順行性の心外膜冠動脈注入
|
US9149473B2
(en)
|
2006-09-14 |
2015-10-06 |
Ibis Biosciences, Inc. |
Targeted whole genome amplification method for identification of pathogens
|
WO2008104002A2
(en)
|
2007-02-23 |
2008-08-28 |
Ibis Biosciences, Inc. |
Methods for rapid forensic dna analysis
|
US9725485B2
(en)
*
|
2012-05-15 |
2017-08-08 |
University Of Florida Research Foundation, Inc. |
AAV vectors with high transduction efficiency and uses thereof for gene therapy
|
US9611302B2
(en)
|
2007-04-09 |
2017-04-04 |
University Of Florida Research Foundation, Inc. |
High-transduction-efficiency RAAV vectors, compositions, and methods of use
|
HUE030719T2
(en)
*
|
2007-04-09 |
2017-05-29 |
Univ Florida |
RAAV vector formulations and methods comprising tyrosine-modified capsid proteins for their use
|
US9598724B2
(en)
|
2007-06-01 |
2017-03-21 |
Ibis Biosciences, Inc. |
Methods and compositions for multiple displacement amplification of nucleic acids
|
EP2058401A1
(de)
*
|
2007-10-05 |
2009-05-13 |
Genethon |
Weitverbreitete Genverabreichung an Motorneuronen unter Verwendung einer peripheren Injektion von AAV-Vektoren
|
CN102159713A
(zh)
|
2008-05-20 |
2011-08-17 |
Eos神经科学公司 |
用于递送光敏蛋白的载体和使用方法
|
US9217155B2
(en)
|
2008-05-28 |
2015-12-22 |
University Of Massachusetts |
Isolation of novel AAV'S and uses thereof
|
EP2344893B1
(de)
|
2008-09-16 |
2014-10-15 |
Ibis Biosciences, Inc. |
Mikroplatten-handhabungssysteme und verfahren
|
US8550694B2
(en)
|
2008-09-16 |
2013-10-08 |
Ibis Biosciences, Inc. |
Mixing cartridges, mixing stations, and related kits, systems, and methods
|
US8148163B2
(en)
|
2008-09-16 |
2012-04-03 |
Ibis Biosciences, Inc. |
Sample processing units, systems, and related methods
|
EP2396803A4
(de)
|
2009-02-12 |
2016-10-26 |
Ibis Biosciences Inc |
Ionisationssondenanordnungen
|
TR201906398T4
(tr)
|
2009-04-30 |
2019-05-21 |
Univ Pennsylvania |
Salgı bezleriyle ilişkili virüs yapılarını içeren iletken hava yolu hücrelerinin hedeflenmesine yönelik bileşimler.
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
WO2010143761A1
(ko)
*
|
2009-06-12 |
2010-12-16 |
(주)바이오니아 |
미지시료 내 감염성 미생물을 신속하게 검출하는 방법
|
US8950604B2
(en)
|
2009-07-17 |
2015-02-10 |
Ibis Biosciences, Inc. |
Lift and mount apparatus
|
EP2454000A4
(de)
|
2009-07-17 |
2016-08-10 |
Ibis Biosciences Inc |
Systeme zur identifizierung von biowirkstoffen
|
US20120244127A1
(en)
|
2009-10-01 |
2012-09-27 |
The Trustees Of The University Of Pennsylvania |
AAV Vectors Expressing SEC10 for Treating Kidney Damage
|
EP3225695A1
(de)
|
2009-10-15 |
2017-10-04 |
Ibis Biosciences, Inc. |
Multiple-displacement-amplifikation
|
US9315825B2
(en)
|
2010-03-29 |
2016-04-19 |
The Trustees Of The University Of Pennsylvania |
Pharmacologically induced transgene ablation system
|
CN102869779A
(zh)
|
2010-03-29 |
2013-01-09 |
宾夕法尼亚大学托管会 |
药理学诱导的转基因消融***
|
WO2011133874A1
(en)
|
2010-04-23 |
2011-10-27 |
University Of Massachusetts |
Multicistronic expression constructs
|
JP2013533847A
(ja)
|
2010-04-23 |
2013-08-29 |
ユニバーシティ オブ マサチューセッツ |
コレステロール関連障害のaavベースの治療
|
EP2826860B1
(de)
|
2010-04-23 |
2018-08-22 |
University of Massachusetts |
Auf das ZNS abzielende AAV Vektoren und Verfahren zur Verwendung davon
|
US9309534B2
(en)
|
2010-07-12 |
2016-04-12 |
Universidad Autonoma De Barcelona |
Gene therapy composition for use in diabetes treatment
|
US8663624B2
(en)
|
2010-10-06 |
2014-03-04 |
The Regents Of The University Of California |
Adeno-associated virus virions with variant capsid and methods of use thereof
|
US20140031418A1
(en)
|
2011-04-20 |
2014-01-30 |
The Trustees Of The University Of Pennsylvania |
Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens
|
EP3318634A1
(de)
|
2011-04-21 |
2018-05-09 |
University of Massachusetts |
Raav-basierte zusammensetzungen und verfahren zur behandlung von krankheiten, die durch dominant-negative oder verbesserung von funktions-mutationen verursacht werden
|
CN103561774B
(zh)
|
2011-04-22 |
2016-12-14 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体及其使用方法
|
EP2748185A1
(de)
*
|
2011-08-24 |
2014-07-02 |
The Board of Trustees of The Leland Stanford Junior University |
Neue aav-capsid-proteine zum transport von nukleinsäuren
|
US20130136729A1
(en)
*
|
2011-11-11 |
2013-05-30 |
University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group |
Compositions and methods for targeting and treating diseases and injuries using adeno-associated virus vectors
|
KR102057540B1
(ko)
*
|
2012-02-17 |
2019-12-19 |
더 칠드런스 호스피탈 오브 필라델피아 |
세포, 기관 및 조직으로의 유전자 전이를 위한 aav 벡터 조성물 및 방법
|
US10093947B2
(en)
*
|
2012-02-28 |
2018-10-09 |
Cornell University |
AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
|
WO2013154744A1
(en)
*
|
2012-04-13 |
2013-10-17 |
Cornell University |
Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
|
US10294281B2
(en)
|
2012-05-15 |
2019-05-21 |
University Of Florida Research Foundation, Incorporated |
High-transduction-efficiency rAAV vectors, compositions, and methods of use
|
EP2692868A1
(de)
|
2012-08-02 |
2014-02-05 |
Universitat Autònoma De Barcelona |
Adenoassoziierte virale (AAV) Vektoren für die Transduktion von Fettgewebe
|
ES2741502T3
(es)
|
2013-02-08 |
2020-02-11 |
Univ Pennsylvania |
Cápside de AAV8 modificada para la transferencia génica para terapias de retina
|
EP4223772A3
(de)
|
2013-02-15 |
2023-10-18 |
Bioverativ Therapeutics Inc. |
Optimiertes faktor-viii-gen
|
US8957044B2
(en)
|
2013-03-01 |
2015-02-17 |
Wake Forest University Health Sciences |
Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
|
EP2984166B1
(de)
|
2013-03-15 |
2020-04-22 |
The Trustees Of The University Of Pennsylvania |
Zusammensetzungen zur behandlung von mpsi
|
US9719106B2
(en)
|
2013-04-29 |
2017-08-01 |
The Trustees Of The University Of Pennsylvania |
Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
|
CN105247044B
(zh)
|
2013-05-31 |
2021-05-07 |
加利福尼亚大学董事会 |
腺相关病毒变体及其使用方法
|
KR102380265B1
(ko)
|
2013-07-22 |
2022-03-29 |
더 칠드런스 호스피탈 오브 필라델피아 |
변종 aav 및 조성물, 세포, 기관 및 조직으로의 유전자 전이를 위한 방법 및 용도
|
SI3099333T1
(sl)
|
2014-01-31 |
2021-04-30 |
Temple University of the Commonwealth System of Higher Education 1938 Liacouras Walk |
BAG3 kot tarča za terapijo srčne odpovedi
|
GB201403684D0
(en)
|
2014-03-03 |
2014-04-16 |
King S College London |
Vector
|
WO2015127128A2
(en)
|
2014-02-19 |
2015-08-27 |
University Of Massachusetts |
Recombinant aavs having useful transcytosis properties
|
KR102390075B1
(ko)
|
2014-03-09 |
2022-04-26 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
오르니틴 트랜스카르바밀라아제(otc) 결핍증의 치료에 유용한 조성물
|
KR102537394B1
(ko)
|
2014-03-17 |
2023-05-30 |
애드베룸 바이오테크놀로지스, 인코포레이티드 |
원추세포에서 증강된 유전자 발현을 위한 조성물 및 방법
|
DK3119797T3
(da)
|
2014-03-18 |
2021-03-15 |
Univ Massachusetts |
Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
|
SI3119437T1
(sl)
|
2014-03-21 |
2020-01-31 |
Genzyme Corporation |
Genska terapija za retinitis pigmentoza
|
EP2933335A1
(de)
|
2014-04-18 |
2015-10-21 |
Genethon |
Verfahren zur Behandlung peripherer Neuropathien und Motoneuronerkrankungen
|
US10780182B2
(en)
|
2014-04-25 |
2020-09-22 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for treating metastatic breast cancer and other cancers in the brain
|
ES2876409T3
(es)
|
2014-04-25 |
2021-11-12 |
Univ Pennsylvania |
Variantes del RLBD y su uso en composiciones para reducir los niveles de colesterol
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
CR20160519A
(es)
|
2014-05-13 |
2017-01-27 |
The Trustees Of The Univ Of Pennysylvania |
Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos
|
US10689653B2
(en)
|
2014-06-03 |
2020-06-23 |
University Of Massachusetts |
Compositions and methods for modulating dysferlin expression
|
US10577627B2
(en)
|
2014-06-09 |
2020-03-03 |
Voyager Therapeutics, Inc. |
Chimeric capsids
|
EP2960336A1
(de)
|
2014-06-27 |
2015-12-30 |
Genethon |
Effiziente systemische Behandlung von Muskeldystrophie
|
BR112016030730B1
(pt)
|
2014-07-03 |
2023-05-02 |
Board Of Regents, The University Of Texas System |
Composto
|
WO2016044478A1
(en)
|
2014-09-16 |
2016-03-24 |
Genzyme Corporation |
Adeno-associated viral vectors for treating myocilin (myoc) glaucoma
|
EP4012035A1
(de)
|
2014-09-16 |
2022-06-15 |
Genzyme Corporation |
Adeno-assoziierte virale vektoren zur behandlung von myocilin (myoc)-glaukom
|
WO2016054554A1
(en)
*
|
2014-10-03 |
2016-04-07 |
University Of Massachusetts |
Heterologous targeting peptide grafted aavs
|
EP3795580A1
(de)
|
2014-10-03 |
2021-03-24 |
University of Massachusetts |
Hocheffiziente bibliotheksidentifizierte aav-vektoren
|
JP7023108B2
(ja)
|
2014-10-21 |
2022-02-21 |
ユニバーシティ オブ マサチューセッツ |
組み換えaavバリアントおよびその使用
|
CN107106689A
(zh)
|
2014-11-05 |
2017-08-29 |
沃雅戈治疗公司 |
用于治疗帕金森病的aadc多核苷酸
|
US10597660B2
(en)
|
2014-11-14 |
2020-03-24 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
SG10202001102XA
(en)
|
2014-11-14 |
2020-03-30 |
Voyager Therapeutics Inc |
Modulatory polynucleotides
|
EP3230441A4
(de)
|
2014-12-12 |
2018-10-03 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur herstellung von scaav
|
EP3978614A3
(de)
|
2015-01-07 |
2022-07-27 |
Universitat Autònoma de Barcelona |
Einzelvektor-genkonstrukt mit insulin und glucokinasegenen
|
WO2016115503A1
(en)
|
2015-01-16 |
2016-07-21 |
Voyager Therapeutics, Inc. |
Central nervous system targeting polynucleotides
|
IL310375A
(en)
|
2015-01-20 |
2024-03-01 |
Genzyme Corp |
Analytical ultracentrifugation for characterization of recombinant viral particles
|
WO2016126857A1
(en)
*
|
2015-02-03 |
2016-08-11 |
University Of Florida Research Foundation, Inc. |
Recombinant aav1, aav5, and aav6 capsid mutants and uses thereof
|
JP6929791B2
(ja)
|
2015-02-09 |
2021-09-01 |
デューク ユニバーシティ |
エピゲノム編集のための組成物および方法
|
CN116019934A
(zh)
|
2015-02-10 |
2023-04-28 |
建新公司 |
病毒颗粒至纹状体和皮质的增强递送
|
JP2018506304A
(ja)
|
2015-02-10 |
2018-03-08 |
ジェンザイム・コーポレーション |
バリアントRNAi
|
WO2016131009A1
(en)
|
2015-02-13 |
2016-08-18 |
University Of Massachusetts |
Compositions and methods for transient delivery of nucleases
|
CN114480502A
(zh)
|
2015-03-02 |
2022-05-13 |
阿德夫拉姆生物技术股份有限公司 |
用于将多核苷酸玻璃体内递送到视网膜视锥的组合物和方法
|
SG11201707116QA
(en)
|
2015-03-10 |
2017-09-28 |
Univ Columbia |
Recombinant glut1 adeno-associated viral vector constructs and related methods for restoring glut1 expression
|
WO2016154344A1
(en)
|
2015-03-24 |
2016-09-29 |
The Regents Of The University Of California |
Adeno-associated virus variants and methods of use thereof
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
WO2016172155A1
(en)
|
2015-04-23 |
2016-10-27 |
University Of Massachusetts |
Modulation of aav vector transgene expression
|
EP3285780A4
(de)
|
2015-04-24 |
2018-12-19 |
University of Massachusetts |
Modifizierte aav-konstruktionen und verwendungen davon
|
US20180110877A1
(en)
|
2015-04-27 |
2018-04-26 |
The Trustees Of The University Of Pennsylvania |
DUAL AAV VECTOR SYSTEM FOR CRISPR/Cas9 MEDIATED CORRECTION OF HUMAN DISEASE
|
GB201508026D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Capsid
|
WO2016200543A2
(en)
|
2015-05-13 |
2016-12-15 |
The Trustees Of The University Of Pennsylvania |
Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
|
BR112017024514A2
(pt)
|
2015-05-16 |
2018-07-24 |
Genzyme Corporation |
edição genética de mutações intrônicas profundas
|
KR102415896B1
(ko)
|
2015-06-23 |
2022-06-30 |
더 칠드런스 호스피탈 오브 필라델피아 |
변형된 인자 ix, 및 세포, 기관 및 조직으로 유전자를 전달하기 위한 조성물, 방법 및 용도
|
WO2017015637A1
(en)
|
2015-07-22 |
2017-01-26 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
KR20180057609A
(ko)
|
2015-08-06 |
2018-05-30 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Glp-1 및 대사성 질환 치료용 조성물에서 이의 용도
|
KR20180038558A
(ko)
|
2015-08-25 |
2018-04-16 |
듀크 유니버시티 |
Rna-가이드된 엔도뉴클레아제를 이용하는 게놈 조작에서 특이성을 개선하는 조성물 및 방법
|
CN108137664B
(zh)
|
2015-08-31 |
2021-11-26 |
宾夕法尼亚州大学信托人 |
用于治疗伴侣动物的aav-epo
|
RU2727411C2
(ru)
|
2015-09-24 |
2020-07-21 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Композиция и способ для лечения заболевания, опосредованного комплементом
|
DK3356390T3
(da)
|
2015-09-28 |
2021-04-12 |
Univ North Carolina Chapel Hill |
Fremgangsmåder og sammensætninger til virusvektorer, der undgår antistoffer
|
US11273227B2
(en)
|
2015-10-09 |
2022-03-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful in treating Stargardt's disease and other ocular disorders
|
EP4089175A1
(de)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genom-engineering mit typ-i-crispr-systemen in eukaryotischen zellen
|
DK3364997T3
(da)
|
2015-10-22 |
2024-04-22 |
Univ Massachusetts |
Aspartoacylase genterapi til behandling af canavans sygdom
|
EP3364996B1
(de)
|
2015-10-22 |
2021-08-25 |
University of Massachusetts |
Gegen die prostata gerichtete adeno-assoziierte virusserotypvektoren
|
BR112018008407A2
(pt)
|
2015-10-28 |
2018-11-27 |
Univ Pennsylvania |
administração intratecal de vetores virais adenoassociados para terapia genética
|
WO2017075335A1
(en)
|
2015-10-28 |
2017-05-04 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
JP2019502363A
(ja)
|
2015-10-30 |
2019-01-31 |
エヌビーイー セラピューティクス アクチェン ゲゼルシャフト |
抗ror1抗体
|
CA3006569A1
(en)
|
2015-12-02 |
2017-06-08 |
Voyager Therapeutics, Inc. |
Assays for the detection of aav neutralizing antibodies
|
FR3044926B1
(fr)
|
2015-12-09 |
2020-01-31 |
Genethon |
Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine
|
US11015173B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV1
|
US11015174B2
(en)
|
2015-12-11 |
2021-05-25 |
The Trustees Of The University Of Pennsylvania |
Scalable purification method for AAV8
|
EP3387118B1
(de)
|
2015-12-11 |
2022-04-06 |
The Trustees Of The University Of Pennsylvania |
Skalierbares reinigungsverfahren für aavrh10
|
EP3400304B1
(de)
|
2015-12-11 |
2022-04-06 |
The Trustees Of The University Of Pennsylvania |
Gentherapeutische behandlung der familiären hypercholesterinämie
|
EP3387138B1
(de)
|
2015-12-11 |
2022-01-26 |
The Trustees Of The University Of Pennsylvania |
Skalierbares reinigungsverfahren für aav9
|
WO2017106202A2
(en)
|
2015-12-14 |
2017-06-22 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
AU2016370590B2
(en)
|
2015-12-14 |
2023-11-02 |
The Trustees Of The University Of Pennsylvania |
Composition for treatment of Crigler-Najjar syndrome
|
EP3390644B1
(de)
|
2015-12-15 |
2024-07-31 |
Genzyme Corporation |
Adeno-assoziierte virale vektoren zur behandlung von mucolipidose typ ii
|
AU2017210327A1
(en)
|
2016-01-20 |
2018-08-09 |
Nbe-Therapeutics Ag |
ROR1 antibody compositions and related methods
|
SG10201913278PA
(en)
|
2016-02-01 |
2020-02-27 |
Bioverativ Therapeutics Inc |
Optimized factor viii genes
|
CA3011939A1
(en)
|
2016-02-02 |
2017-08-10 |
University Of Massachusetts |
Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
|
BR112018015751A2
(pt)
|
2016-02-03 |
2019-02-05 |
Univ Pennsylvania |
terapia gênica para tratamento de mucopolissacaridose tipo i
|
WO2017139643A1
(en)
|
2016-02-12 |
2017-08-17 |
University Of Massachusetts |
Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
|
WO2017151717A1
(en)
*
|
2016-03-01 |
2017-09-08 |
French Brent A |
Compositions and methods for adeno-associated virus mediated gene expression in myofibroblast-like cells
|
EP3440210A4
(de)
|
2016-04-05 |
2019-11-27 |
University of Massachusetts |
Zusammensetzungen und verfahren zur selektiven hemmung der expression des grainyhead-like-proteins
|
EP3443001A4
(de)
|
2016-04-11 |
2020-04-29 |
Obsidian Therapeutics, Inc. |
Regulierte bioschaltkreissysteme
|
WO2017180861A1
(en)
|
2016-04-15 |
2017-10-19 |
The Trustees Of The University Of Pennsulvania |
Gene therapy for treating hemophilia b
|
WO2017181105A1
(en)
|
2016-04-15 |
2017-10-19 |
University Of Massachusetts |
Methods and compositions for treating metabolic imbalance
|
JP7140683B2
(ja)
*
|
2016-04-15 |
2022-09-21 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
新規なaav8変異カプシド及びそれを含有する組成物
|
EP3452103A1
(de)
|
2016-04-15 |
2019-03-13 |
The Trustees Of The University Of Pennsylvania |
Zusammensetzungen zur behandlung von nasser altersbedingter makuladegeneration
|
RU2762257C2
(ru)
|
2016-04-15 |
2021-12-17 |
Зе Трастис Оф Зе Юниверсити Оф Пенсильвания |
Генная терапия для лечения гемофилии a
|
AU2017250298A1
(en)
|
2016-04-15 |
2018-10-11 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type II
|
WO2017184463A1
(en)
|
2016-04-17 |
2017-10-26 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for prophylaxis of organophosphates
|
EP3448874A4
(de)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
Zusammensetzungen zur behandlung einer erkrankung
|
US11299751B2
(en)
|
2016-04-29 |
2022-04-12 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
GB201608046D0
(en)
*
|
2016-05-09 |
2016-06-22 |
Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The |
Treatment of complement-mediated disorders
|
AU2017261812B2
(en)
|
2016-05-13 |
2019-04-18 |
4D Molecular Therapeutics Inc. |
Adeno-associated virus variant capsids and methods of use thereof
|
US11951121B2
(en)
|
2016-05-18 |
2024-04-09 |
Voyager Therapeutics, Inc. |
Compositions and methods for treating Huntington's disease
|
CN110214187B
(zh)
|
2016-05-18 |
2024-01-30 |
沃雅戈治疗公司 |
调节性多核苷酸
|
WO2017212929A1
(ja)
*
|
2016-06-08 |
2017-12-14 |
ソニー株式会社 |
撮像制御装置および方法、並びに車両
|
US11882815B2
(en)
|
2016-06-15 |
2024-01-30 |
University Of Massachusetts |
Recombinant adeno-associated viruses for delivering gene editing molecules to embryonic cells
|
CA3029864A1
(en)
|
2016-07-05 |
2018-01-11 |
University Of Massachusetts |
Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
|
JP7101656B2
(ja)
|
2016-07-08 |
2022-07-15 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Rdh12が関与する疾患及び疾病を治療する方法及び組成物
|
US11883470B2
(en)
|
2016-07-25 |
2024-01-30 |
The Trustees Of The University Of Pennsylvania |
Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof
|
IL305149A
(en)
|
2016-07-26 |
2023-10-01 |
Biomarin Pharm Inc |
Novel adeno-associated virus capsid proteins
|
CN114672516A
(zh)
|
2016-07-29 |
2022-06-28 |
加利福尼亚大学董事会 |
具有变异衣壳的腺相关病毒病毒体和其使用方法
|
CA3033856A1
(en)
|
2016-08-15 |
2018-02-22 |
Genzyme Corporation |
Methods for detecting aav
|
EP3831281A1
(de)
|
2016-08-30 |
2021-06-09 |
The Regents of The University of California |
Verfahren für biomedizinisches targeting und freisetzung sowie vorrichtungen und systeme zur ausführung davon
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
WO2018064624A1
(en)
*
|
2016-09-29 |
2018-04-05 |
University Of Florida Research Foundation, Incorporated |
Aavrh.10 variants with host antibody escape capabilities and altered tissue targeting properties
|
JP2019530463A
(ja)
|
2016-10-13 |
2019-10-24 |
ユニバーシティ オブ マサチューセッツ |
Aavカプシド設計
|
AU2017345470B2
(en)
|
2016-10-19 |
2023-08-03 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
EP3548065B1
(de)
|
2016-12-01 |
2022-11-09 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Pharmazeutische zusammensetzungen zur behandlung von degenerativen netzhauterkrankungen
|
US11584931B2
(en)
|
2016-12-14 |
2023-02-21 |
The J. David Gladstone Institutes |
Methods and compositions for generating a deletion library and for identifying a defective interfering particle (DIP)
|
WO2018126112A1
(en)
*
|
2016-12-30 |
2018-07-05 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating phenylketonuria
|
WO2018136710A1
(en)
|
2017-01-20 |
2018-07-26 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Treatment of krabbe disease with umbilical cord blood transplantion (ucbt) and increased galactocerebrosidase (galc) expression
|
US11554147B2
(en)
|
2017-02-20 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating familial hypercholesterolemia
|
AU2018229293A1
(en)
|
2017-02-28 |
2019-08-29 |
Janssen Biotech, Inc. |
Influenza vaccines based on AAV vectors
|
CA3053399A1
(en)
|
2017-02-28 |
2018-09-07 |
The Trustees Of The University Of Pennsylvania |
Novel adeno-associated virus (aav) clade f vector and uses therefor
|
JOP20190200A1
(ar)
|
2017-02-28 |
2019-08-27 |
Univ Pennsylvania |
تركيبات نافعة في معالجة ضمور العضل النخاعي
|
KR102545070B1
(ko)
|
2017-03-01 |
2023-06-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
안구 장애에 대한 유전자 치료
|
EP3589311A1
(de)
|
2017-03-02 |
2020-01-08 |
Genethon |
Verfahren zur entfernung von anti-aav-antikörpern aus einer aus blut stammenden zusammensetzung
|
CN118360335A
(zh)
|
2017-04-05 |
2024-07-19 |
马萨诸塞大学 |
小基因治疗
|
US11499154B2
(en)
|
2017-04-10 |
2022-11-15 |
Genethon |
Antisense targeting dynamin 2 and use for the treatment of centronuclear myopathies and neuropathies
|
UY37679A
(es)
|
2017-04-14 |
2018-11-30 |
Regenxbio Inc |
Tratamiento de mucopolisacaridosis ii con iduronato-2-sulfatasa (ids) humana recombinante producida por células neurales o gliales humanas
|
WO2018200542A1
(en)
|
2017-04-24 |
2018-11-01 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for ocular disorders
|
US11603542B2
(en)
|
2017-05-05 |
2023-03-14 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
|
CA3061368A1
(en)
|
2017-05-05 |
2018-11-08 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating huntington's disease
|
EP3622073A4
(de)
|
2017-05-09 |
2021-01-06 |
University of Massachusetts |
Verfahren zur behandlung von amyotropher lateralsklerose (als)
|
BR112019023303A2
(pt)
|
2017-05-11 |
2020-06-16 |
The Trustees Of The University Of Pennsylvania |
Terapia de gene para lipofuscinoses ceroides neuronais
|
JP2020519294A
(ja)
|
2017-05-12 |
2020-07-02 |
ユニバーシティ オブ マサチューセッツ |
ウイルスベクター産生
|
CN108103058A
(zh)
*
|
2017-05-12 |
2018-06-01 |
北京五加和分子医学研究所有限公司 |
一种i型糖尿病的基因治疗药物
|
WO2018218359A1
(en)
|
2017-05-31 |
2018-12-06 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating peroxisomal disorders
|
BR112019025732A2
(pt)
|
2017-06-06 |
2020-06-30 |
University Of Massachusetts |
vetores de aav auto-reguladores para expressão segura de mecp2 na síndrome de rett
|
EP3638316A4
(de)
|
2017-06-14 |
2021-03-24 |
The Trustees Of The University Of Pennsylvania |
Gentherapie für augenerkrankungen
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
US10693918B2
(en)
|
2017-06-15 |
2020-06-23 |
Palo Alto Networks, Inc. |
Radio access technology based security in service provider networks
|
US10721272B2
(en)
|
2017-06-15 |
2020-07-21 |
Palo Alto Networks, Inc. |
Mobile equipment identity and/or IOT equipment identity and application identity based security enforcement in service provider networks
|
US10812532B2
(en)
|
2017-06-15 |
2020-10-20 |
Palo Alto Networks, Inc. |
Security for cellular internet of things in mobile networks
|
US10834136B2
(en)
|
2017-06-15 |
2020-11-10 |
Palo Alto Networks, Inc. |
Access point name and application identity based security enforcement in service provider networks
|
US10708306B2
(en)
|
2017-06-15 |
2020-07-07 |
Palo Alto Networks, Inc. |
Mobile user identity and/or SIM-based IoT identity and application identity based security enforcement in service provider networks
|
US11050789B2
(en)
|
2017-06-15 |
2021-06-29 |
Palo Alto Networks, Inc. |
Location based security in service provider networks
|
WO2018237300A1
(en)
*
|
2017-06-22 |
2018-12-27 |
Board Of Regents, The University Of Texas System |
METHODS OF GENERATING REGULATORY IMMUNE CELLS AND USES THEREOF
|
WO2019010335A1
(en)
|
2017-07-06 |
2019-01-10 |
The Trustees Of The University Of Pennsylvania |
AAV9 MEDIATED GENE THERAPY FOR TREATING MUCOPOLYSACCHARIDOSIS TYPE I
|
JP7141417B2
(ja)
|
2017-07-07 |
2022-09-22 |
ジェネトン |
ヒトfkrpタンパク質をコードする新規ポリヌクレオチド
|
EP3654860A1
(de)
|
2017-07-17 |
2020-05-27 |
Voyager Therapeutics, Inc. |
Trajektoriearrayführungssystem
|
EP3808849A1
(de)
|
2017-08-03 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur aav-freisetzung
|
WO2019030223A1
(en)
|
2017-08-07 |
2019-02-14 |
Nbe-Therapeutics Ag |
ANTHRACYCLINE ANTIBODY-MEDICINAL CONJUGATES HAVING HIGH IN VIVO TOLERABILITY
|
AU2018324477A1
(en)
*
|
2017-08-28 |
2019-10-17 |
The Regents Of The University Of California |
Adeno-associated virus capsid variants and methods of use thereof
|
SG11202002276VA
(en)
|
2017-09-20 |
2020-04-29 |
4D Molecular Therapeutics Inc |
Adeno-associated virus variant capsids and methods of use thereof
|
JP7449223B2
(ja)
|
2017-09-22 |
2024-03-13 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ムコ多糖症ii型を治療するための遺伝子療法
|
AR113134A1
(es)
|
2017-09-22 |
2020-01-29 |
Genzyme Corp |
Arni variante
|
CA3075643A1
(en)
|
2017-09-22 |
2019-03-28 |
University Of Massachusetts |
Sod1 dual expression vectors and uses thereof
|
US11807849B2
(en)
*
|
2017-10-03 |
2023-11-07 |
Prevail Therapeutics, Inc. |
Gene therapies for lysosomal disorders
|
EP3697905A1
(de)
|
2017-10-16 |
2020-08-26 |
Voyager Therapeutics, Inc. |
Behandlung von amyotropher lateralsklerose (als)
|
US20200237799A1
(en)
|
2017-10-16 |
2020-07-30 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis (als)
|
WO2019079494A1
(en)
|
2017-10-18 |
2019-04-25 |
Regenxbio, Inc. |
TREATMENT OF OCULAR DISEASES AND METASTATIC COLON CANCER WITH A VEGF TRAP WITH HUMAN POST-TRANSLATIONAL MODIFICATION
|
KR20200067195A
(ko)
|
2017-10-18 |
2020-06-11 |
리젠엑스바이오 인크. |
완전-인간 번역후 변형된 항체 치료제
|
WO2019079632A1
(en)
|
2017-10-18 |
2019-04-25 |
Board Of Regents, The University Of Texas System |
GLUTAMINASE INHIBITOR THERAPY
|
FI3717636T3
(fi)
|
2017-11-27 |
2023-06-01 |
4D Molecular Therapeutics Inc |
Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä
|
AU2018375163A1
(en)
|
2017-11-30 |
2020-06-11 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis IIIB
|
US11555206B2
(en)
|
2017-11-30 |
2023-01-17 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for mucopolysaccharidosis IIIA
|
WO2019126329A1
(en)
|
2017-12-19 |
2019-06-27 |
Akouos Llc |
Aav-mediated delivery of therapeutic antibodies to the inner ear
|
US10610606B2
(en)
|
2018-02-01 |
2020-04-07 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
|
WO2019161365A1
(en)
|
2018-02-19 |
2019-08-22 |
Homology Medicines, Inc. |
Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof
|
EP3762500A1
(de)
|
2018-03-06 |
2021-01-13 |
Voyager Therapeutics, Inc. |
Aus insektenzelle hergestellte teilweise selbstkomplementäre aav-genome
|
CA3094217A1
(en)
|
2018-03-23 |
2019-09-26 |
University Of Massachusetts |
Gene therapeutics for treating bone disorders
|
BR112020020266A2
(pt)
|
2018-04-03 |
2021-01-19 |
Stridebio, Inc. |
Vetores de vírus com evasão de anticorpos
|
WO2019200016A1
(en)
|
2018-04-10 |
2019-10-17 |
President And Fellows Of Harvard College |
Aav vectors encoding clarin-1 or gjb2 and uses thereof
|
US11981892B2
(en)
|
2018-04-16 |
2024-05-14 |
University Of Massachusetts |
Compositions and methods for improved gene editing
|
US11472848B2
(en)
|
2018-04-27 |
2022-10-18 |
University Of Massachusetts |
AAV capsids identified by in vivo library selection
|
EP3787771A1
(de)
|
2018-04-29 |
2021-03-10 |
REGENXBIO Inc. |
Skalierbares klärungsverfahren für die rekombinante aav-produktion
|
EP3788165A1
(de)
|
2018-04-29 |
2021-03-10 |
REGENXBIO Inc. |
Systeme und verfahren zur spektralfotometrie zur bestimmung des genomgehalts, des kapsidgehalts und der voll-/leer-verhältnisse von adeno-assoziierten viruspartikeln
|
WO2019217582A1
(en)
|
2018-05-08 |
2019-11-14 |
Rutgers, The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
SG11202010830WA
(en)
|
2018-05-09 |
2020-11-27 |
Biomarin Pharm Inc |
Methods of treating phenylketonuria
|
TW202005978A
(zh)
|
2018-05-14 |
2020-02-01 |
美商拜奧馬林製藥公司 |
新穎肝靶向腺相關病毒載體
|
EP3793616A1
(de)
|
2018-05-15 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur aav-freisetzung
|
CA3099306A1
(en)
|
2018-05-15 |
2019-11-21 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of parkinson's disease
|
EP3793686A1
(de)
|
2018-05-16 |
2021-03-24 |
Voyager Therapeutics, Inc. |
Aav-serotypen zur gehirnspezifischen payload-übertragung
|
US20210214749A1
(en)
|
2018-05-16 |
2021-07-15 |
Voyager Therapeutics, Inc. |
Directed evolution
|
EP3806888B1
(de)
|
2018-06-12 |
2024-01-31 |
Obsidian Therapeutics, Inc. |
Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie
|
EP3807404A1
(de)
|
2018-06-13 |
2021-04-21 |
Voyager Therapeutics, Inc. |
Manipulierte 5'-unübersetzte regionen (5' utr) zur herstellung von aav
|
CN112469822A
(zh)
|
2018-06-14 |
2021-03-09 |
再生生物股份有限公司 |
用于重组aav生产的阴离子交换色谱
|
WO2020010042A1
(en)
|
2018-07-02 |
2020-01-09 |
Voyager Therapeutics, Inc. |
Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
CN113302202B
(zh)
|
2018-07-17 |
2024-01-30 |
赫利世弥斯株式会社 |
利用表达***1异构体的脱氧核糖核酸构建体的神经病变的治疗
|
WO2020023612A1
(en)
|
2018-07-24 |
2020-01-30 |
Voyager Therapeutics, Inc. |
Systems and methods for producing gene therapy formulations
|
EP3831949A4
(de)
*
|
2018-07-30 |
2022-05-04 |
Gene Therapy Research Institution Co., Ltd. |
Verfahren zur erhöhung der genexpression durch einen aav-vektor
|
WO2020028816A1
(en)
|
2018-08-03 |
2020-02-06 |
Genzyme Corporation |
Variant rnai against alpha-synuclein
|
KR20210043580A
(ko)
|
2018-08-10 |
2021-04-21 |
리젠엑스바이오 인크. |
재조합 aav 생산을 위한 규모 조정 가능한 방법
|
WO2020047467A2
(en)
|
2018-08-30 |
2020-03-05 |
Tenaya Therapeutics, Inc. |
Cardiac cell reprogramming with myocardin and ascl1
|
CN113383010A
(zh)
|
2018-09-28 |
2021-09-10 |
沃雅戈治疗公司 |
具有经工程化改造的启动子的共济蛋白表达构建体及其使用方法
|
US20210403923A1
(en)
|
2018-09-28 |
2021-12-30 |
President And Fellows Of Harvard College |
Mutant reverse tetracycline transactivators for expression of genes
|
EP3856226A1
(de)
|
2018-09-28 |
2021-08-04 |
President and Fellows of Harvard College |
Zelluläre umprogrammierung zur umkehrung der alterung und zur förderung der organ- und geweberegeneration
|
BR112021006060A2
(pt)
|
2018-10-01 |
2021-07-20 |
The Trustees Of The University Of Pennsylvania |
composições úteis para tratamento de gangliosidose gm1
|
EP3861113A1
(de)
|
2018-10-04 |
2021-08-11 |
Voyager Therapeutics, Inc. |
Verfahren zur messung des titers und der potenz von viralen vektorpartikeln
|
CN113166731A
(zh)
|
2018-10-05 |
2021-07-23 |
沃雅戈治疗公司 |
编码aav生产蛋白的工程化核酸构建体
|
CA3116283A1
(en)
|
2018-10-12 |
2020-04-16 |
Genzyme Corporation |
Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
JP2022505106A
(ja)
|
2018-10-15 |
2022-01-14 |
ボイジャー セラピューティクス インコーポレイテッド |
バキュロウイルス/Sf9システムにおけるrAAVの大規模産生のための発現ベクター
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
JP2022514112A
(ja)
|
2018-10-15 |
2022-02-09 |
リジェネクスバイオ インコーポレイテッド |
複製欠損型ウイルスベクター及びウイルスの感染性を測定するための方法
|
MX2021004602A
(es)
|
2018-10-22 |
2021-09-08 |
Univ Rochester |
Edición del genoma por inserción no homóloga de adn dirigida utilizando una proteína de fusión retroviral integrasacas9.
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
EP3650956A1
(de)
|
2018-11-07 |
2020-05-13 |
Tissot S.A. |
Verbreitungsverfahren eines akustischen signals
|
CN113316639A
(zh)
*
|
2018-11-16 |
2021-08-27 |
阿斯克肋匹奥生物制药公司 |
用于治疗庞贝氏病的治疗性腺相关病毒
|
TW202033224A
(zh)
|
2018-11-16 |
2020-09-16 |
日商安斯泰來製藥股份有限公司 |
藉靶向肌營養相關蛋白基因治療肌肉萎縮症之方法
|
EP3887522A1
(de)
|
2018-11-29 |
2021-10-06 |
University of Massachusetts |
Modulation von sptlc1 über rekombinante adeno-assoziierte vektoren
|
WO2020140007A1
(en)
|
2018-12-28 |
2020-07-02 |
University Of Rochester |
Gene therapy for best1 dominant mutations
|
KR20210112339A
(ko)
|
2019-01-04 |
2021-09-14 |
울트라제닉스 파마수티컬 인코포레이티드 |
윌슨병을 치료하기 위한 유전자 요법 구축물
|
US20220090088A1
(en)
|
2019-01-14 |
2022-03-24 |
University Of Rochester |
Targeted Nuclear RNA Cleavage and Polyadenylation with CRISPR-Cas
|
TW202039858A
(zh)
|
2019-01-18 |
2020-11-01 |
美商航海家醫療公司 |
用於生產aav顆粒之方法及系統
|
EP3917566A4
(de)
|
2019-01-31 |
2022-10-26 |
Oregon Health & Science University |
Verfahren zur verwendung von transkriptionsabhängiger gerichteter entwicklung von aav-kapsiden
|
JP2022523766A
(ja)
|
2019-02-22 |
2022-04-26 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
Grn関連成人発症性神経変性の治療のための組換えアデノ随伴ウイルス
|
CA3131023A1
(en)
|
2019-02-22 |
2020-08-27 |
Michael R. Volkert |
Oxr1 gene therapy
|
US20220154211A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Compositions and methods to treat bietti crystalline dystrophy
|
MX2021010149A
(es)
|
2019-02-25 |
2021-09-14 |
Novartis Ag |
Composiciones y metodos para tratar la distrofia cristalina de bietti.
|
CA3130055A1
(en)
|
2019-02-26 |
2020-09-03 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of krabbe disease
|
JP2022522756A
(ja)
|
2019-02-28 |
2022-04-20 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
治療薬の送達のためのアデノ随伴ウイルスベクター
|
MX2021011468A
(es)
|
2019-03-21 |
2021-12-15 |
|
Vectores de virus adenoasociados recombinantes.
|
EP3947427A1
(de)
|
2019-03-25 |
2022-02-09 |
Genethon |
Herstellung von grossen quasidystrophinen mit überlappenden aav-vektoren
|
JP2022521851A
(ja)
|
2019-04-03 |
2022-04-12 |
レジェンクスバイオ インコーポレーテッド |
眼の病態に対する遺伝子療法
|
TW202102526A
(zh)
|
2019-04-04 |
2021-01-16 |
美商銳進科斯生物股份有限公司 |
重組腺相關病毒及其用途
|
US20220275358A1
(en)
|
2019-04-11 |
2022-09-01 |
Regenxbio Inc. |
Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions
|
EP3956456A1
(de)
|
2019-04-17 |
2022-02-23 |
Codiak BioSciences, Inc. |
Zusammensetzungen von exosomen und aav
|
CN113993552A
(zh)
|
2019-04-19 |
2022-01-28 |
再生生物股份有限公司 |
腺相关病毒载体制剂和方法
|
WO2020219868A1
(en)
|
2019-04-24 |
2020-10-29 |
Regenxbio Inc. |
Fully-human post-translationally modified antibody therapeutics
|
SG11202111373YA
(en)
*
|
2019-04-29 |
2021-11-29 |
Univ Pennsylvania |
Novel aav capsids and compositions containing same
|
EP3962536A1
(de)
|
2019-04-29 |
2022-03-09 |
Voyager Therapeutics, Inc. |
Systeme und verfahren zur herstellung von baculovirusinfizierten insektenzellen (biics) in bioreaktoren
|
EP3966227A1
(de)
|
2019-05-07 |
2022-03-16 |
Voyager Therapeutics, Inc. |
Zusammensetzungen und verfahren zur vektorisierten vermehrung von proteinzerstörung, -expression und/oder -regulierung
|
US20220241430A1
(en)
*
|
2019-05-24 |
2022-08-04 |
Regeneron Pharmaceuticals, Inc. |
Modified viral particles and uses thereof
|
WO2020241903A1
(en)
|
2019-05-28 |
2020-12-03 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting dmpk gene
|
US20220348912A1
(en)
|
2019-06-20 |
2022-11-03 |
University Of Massachusetts |
Compositions and methods for improved gene editing
|
KR20220069917A
(ko)
|
2019-07-02 |
2022-05-27 |
엠6피 테라퓨틱스 (스위처랜드) 엘엘씨 |
리소좀 축적 장애의 치료를 위한 벡터 조성물 및 이의 사용 방법
|
US20220251567A1
(en)
|
2019-07-10 |
2022-08-11 |
Inserm (Institut National De La Santè Et De La Recherche Médicale) |
Methods for the treatment of epilepsy
|
ES2964907T3
(es)
|
2019-07-11 |
2024-04-10 |
Centre Nat Rech Scient |
Virus adenoasociado modificado químicamente
|
US20230137971A1
(en)
|
2019-07-11 |
2023-05-04 |
Tenaya Therapeutics Inc. |
Cardiac cell reprogramming with micrornas and other factors
|
US10557149B1
(en)
*
|
2019-07-15 |
2020-02-11 |
Vigene Biosciences, Inc. |
Recombinantly-modified adeno-associated virus helper vectors and their use to improve the packaging efficiency of recombinantly-modified adeno-associated virus
|
US10653731B1
(en)
*
|
2019-07-15 |
2020-05-19 |
Vigene Biosciences Inc. |
Recombinantly-modified adeno-associated virus (rAAV) having improved packaging efficiency
|
JP2022544015A
(ja)
|
2019-07-23 |
2022-10-17 |
ユニバーシティ オブ ロチェスター |
CRISPR-Casでの標的化されたRNA切断
|
WO2021021674A1
(en)
|
2019-07-26 |
2021-02-04 |
Akouos, Inc. |
Methods of treating hearing loss using a secreted target protein
|
US20230042103A1
(en)
|
2019-07-26 |
2023-02-09 |
Regenxbio Inc. |
Engineered nucleic acid regulatory element and methods of uses thereof
|
US20220290182A1
(en)
|
2019-08-09 |
2022-09-15 |
Voyager Therapeutics, Inc. |
Cell culture medium for use in producing gene therapy products in bioreactors
|
WO2021030764A1
(en)
*
|
2019-08-14 |
2021-02-18 |
University Of Florida Research Foundation, Incorporated |
Aav capsid variants for gene therapy
|
WO2021041373A1
(en)
|
2019-08-26 |
2021-03-04 |
Regenxbio Inc. |
Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab
|
EP4022070A1
(de)
|
2019-08-26 |
2022-07-06 |
Voyager Therapeutics, Inc. |
Kontrollierte expression viraler proteine
|
AU2020337919A1
(en)
|
2019-08-27 |
2022-03-24 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of disorders associated with repetitive DNA
|
US20220333133A1
(en)
|
2019-09-03 |
2022-10-20 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
US20220348937A1
(en)
|
2019-09-06 |
2022-11-03 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
AU2020346062A1
(en)
|
2019-09-13 |
2022-03-24 |
Rutgers, The State University Of New Jersey |
AAV-compatible laminin-linker polymerization proteins
|
EP4031673A1
(de)
|
2019-09-19 |
2022-07-27 |
Genethon |
Gentherapieexpressionssystem zur linderung der kardialen toxizität von fkrp
|
WO2021062096A1
(en)
|
2019-09-26 |
2021-04-01 |
Massachusetts Institute Of Technology |
Microrna-based logic gates and uses thereof
|
US11834659B2
(en)
|
2019-09-26 |
2023-12-05 |
Massachusetts Institute Of Technology |
Trans-activated functional RNA by strand displacement and uses thereof
|
US20220347298A1
(en)
|
2019-10-04 |
2022-11-03 |
Ultragenyx Pharmaceutical Inc. |
Methods for improved therapeutic use of recombinant aav
|
CN114728049A
(zh)
|
2019-10-07 |
2022-07-08 |
再生生物股份有限公司 |
腺相关病毒载体药物组合物和方法
|
EP4045665A4
(de)
|
2019-10-15 |
2023-11-15 |
University of Massachusetts |
Rna editor-verstärktes rna-transspleissen
|
US20220403414A1
(en)
*
|
2019-10-16 |
2022-12-22 |
Wuxi Apptec (Shanghai) Co., Ltd. |
Novel aav variant
|
EP4045525A1
(de)
|
2019-10-17 |
2022-08-24 |
Stridebio, Inc. |
Adeno-assoziierte virusvektoren zur behandlung der niemann-pick-krankheit vom typ c
|
CN114829391A
(zh)
|
2019-11-14 |
2022-07-29 |
生物马林药物股份有限公司 |
用肝特异性基因疗法载体治疗遗传性血管性水肿
|
EP4061943A1
(de)
|
2019-11-19 |
2022-09-28 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antisense-oligonukleotide und deren verwendung zur behandlung von krebs
|
JP2023503637A
(ja)
|
2019-11-28 |
2023-01-31 |
リジェネックスバイオ インコーポレイテッド |
マイクロジストロフィン遺伝子治療コンストラクト及びその使用
|
US11981912B2
(en)
|
2019-12-10 |
2024-05-14 |
Takeda Pharma ceutical Company Limited |
Adeno associated virus vectors for the treatment of hunter disease
|
TW202140791A
(zh)
|
2020-01-13 |
2021-11-01 |
美商霍蒙拉奇醫藥公司 |
治療苯酮尿症之方法
|
EP4093428A1
(de)
|
2020-01-22 |
2022-11-30 |
RegenxBio Inc. |
Behandlung von mucopolysaccharidose i mit vollständig menschlicher glykosylierter menschlicher alpha-l-iduronidase (idua)
|
TW202136516A
(zh)
|
2020-01-29 |
2021-10-01 |
美商銳進科斯生物股份有限公司 |
Iva型黏多醣病之治療
|
TW202142695A
(zh)
|
2020-01-29 |
2021-11-16 |
美商銳進科斯生物股份有限公司 |
用人類神經或神經膠質細胞產生之重組人類艾杜糖醛酸—2—硫酸酯酶(ids)對ii型黏多糖病之治療
|
CN115697388A
(zh)
|
2020-01-30 |
2023-02-03 |
优莫佳生物制药股份有限公司 |
双特异性转导增强子
|
CA3165057A1
(en)
|
2020-02-02 |
2021-08-05 |
James M. Wilson |
Compositions useful for treating gm1 gangliosidosis
|
US20230078498A1
(en)
|
2020-02-07 |
2023-03-16 |
University Of Rochester |
Targeted Translation of RNA with CRISPR-Cas13 to Enhance Protein Synthesis
|
US20230073250A1
(en)
|
2020-02-07 |
2023-03-09 |
University Of Rochester |
Ribozyme-mediated RNA Assembly and Expression
|
IL294781A
(en)
|
2020-02-14 |
2022-09-01 |
Ultragenyx Pharmaceutical Inc |
Gene therapy for the treatment of cdkl5-deficient disorder
|
EP4114421A1
(de)
|
2020-03-02 |
2023-01-11 |
Tenaya Therapeutics, Inc. |
Genvektorsteuerung durch kardiomyozyten-exprimierte mikrornas
|
JP2023519344A
(ja)
|
2020-03-27 |
2023-05-10 |
ユニバーシティ オブ ロチェスター |
CRISPR-Cas13 crRNAアレイ
|
JP2023519576A
(ja)
|
2020-03-27 |
2023-05-11 |
ユーシービー バイオファルマ エスアールエル |
自律ノブドメインペプチド
|
US20240218367A1
(en)
|
2020-03-27 |
2024-07-04 |
University Of Rochester |
Targeted Destruction of Viral RNA by CRISPR-Cas13
|
AR122404A1
(es)
|
2020-03-31 |
2022-09-07 |
Univ Massachusetts |
Variantes de cápside y usos de las mismas
|
JP2023520402A
(ja)
|
2020-03-31 |
2023-05-17 |
ウルトラジェニックス ファーマシューティカル インコーポレイテッド |
プロピオン酸血症を処置するための遺伝子治療
|
TW202144575A
(zh)
|
2020-04-03 |
2021-12-01 |
美商拜奧馬林製藥公司 |
使用aav及治療調配物之苯酮尿症治療
|
CN115667289A
(zh)
|
2020-04-10 |
2023-01-31 |
索拉生物科学有限公司 |
用于治疗蛋白聚集障碍的组合物和方法
|
WO2021211753A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
MX2022013288A
(es)
|
2020-04-28 |
2023-02-22 |
Sola Biosciences Llc |
Composiciones y metodos para el tratamiento de proteinopatias por la proteina 43 de union a acido desoxirribonucleico (adn) de respuesta transactiva (tdp-43).
|
IL298137A
(en)
|
2020-05-12 |
2023-01-01 |
Univ Pennsylvania |
The compositions are useful in the treatment of Krabbe's disease
|
AU2021270447A1
(en)
|
2020-05-12 |
2023-01-05 |
The Trustees Of The University Of Pennsylvania |
Compositions for DRG-specific reduction of transgene expression
|
CA3183171A1
(en)
|
2020-05-13 |
2021-11-18 |
Akouos, Inc. |
Compositions and methods for treating slc26a4-associated hearing loss
|
AR122079A1
(es)
|
2020-05-13 |
2022-08-10 |
Akouos Inc |
Composiciones y métodos para tratar la perdida auditiva asociada a kcnq4
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
JP2023529371A
(ja)
|
2020-06-05 |
2023-07-10 |
ソラ・バイオサイエンシズ・エルエルシー |
シヌクレイノパチーの処置のための組成物および方法
|
US20230220069A1
(en)
|
2020-06-17 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of gene therapy patients
|
EP4168052A2
(de)
|
2020-06-19 |
2023-04-26 |
Genethon |
Gentherapie-expressionssystem, das eine adequate expression in den muskeln und im herzen von sgcg ermöglicht
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
JP2023532806A
(ja)
|
2020-07-10 |
2023-07-31 |
ジェネトン |
新規の筋肉特異的プロモーター
|
TW202216244A
(zh)
|
2020-07-13 |
2022-05-01 |
賓州大學委員會 |
有用於治療夏馬杜三氏病之組成物
|
AU2021307447A1
(en)
|
2020-07-15 |
2023-03-09 |
University Of Rochester |
Targeted RNA cleavage with dCas13-RNase fusion proteins
|
WO2022017630A1
(en)
|
2020-07-23 |
2022-01-27 |
Ucl Business Ltd |
GENE THERAPY VECTOR FOR eEF1A2 AND USES THEREOF
|
JP2023536091A
(ja)
|
2020-07-27 |
2023-08-23 |
ボイジャー セラピューティクス インコーポレイテッド |
グルコシルセラミダーゼベータ欠損に関連する神経障害の治療のための組成物及び方法
|
US20230285596A1
(en)
|
2020-07-27 |
2023-09-14 |
Voyager Therapeutics, Inc |
Compositions and methods for the treatment of niemann-pick type c1 disease
|
EP4192514A1
(de)
|
2020-08-06 |
2023-06-14 |
Voyager Therapeutics, Inc. |
Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
|
JP2023538519A
(ja)
|
2020-08-07 |
2023-09-08 |
スペースクラフト セブン リミテッド ライアビリティ カンパニー |
Aavベクターを使用したプラコフィリン-2(pkp2)遺伝子治療
|
KR20230042754A
(ko)
|
2020-08-07 |
2023-03-29 |
아미쿠스 세라퓨틱스, 인코포레이티드 |
소포 표적화 단백질 및 이의 용도
|
CN114075610B
(zh)
*
|
2020-08-11 |
2023-11-17 |
北京荷塘生华医疗科技有限公司 |
检测野生型腺相关病毒的通用引物及其应用
|
CN116209769A
(zh)
|
2020-08-14 |
2023-06-02 |
宾夕法尼亚州大学信托人 |
新型aav衣壳和含有新型aav衣壳的组合物
|
WO2022046815A1
(en)
|
2020-08-24 |
2022-03-03 |
The Trustees Of The University Of Pennsylvania |
Viral vectors encoding glp-1 receptor agonist fusions and uses thereof in treating metabolic diseases
|
GB202013194D0
(en)
|
2020-08-24 |
2020-10-07 |
Combigene Ab |
Gene therapy for lipodystrophy
|
IL300622A
(en)
|
2020-08-26 |
2023-04-01 |
Univ Pennsylvania |
Recombinant adeno-associated virus for the treatment of adult-onset GRN-related neurodegeneration
|
WO2022056000A1
(en)
|
2020-09-09 |
2022-03-17 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of duchenne muscular dystrophy
|
CA3188763A1
(en)
|
2020-09-10 |
2022-03-17 |
Ludwig-Maximilians-Universitat Munchen |
Engineered aav vectors
|
EP4214242A1
(de)
|
2020-09-15 |
2023-07-26 |
RegenxBio Inc. |
Vektorisierte antikörper für antivirale therapie
|
WO2022060915A1
(en)
|
2020-09-15 |
2022-03-24 |
Regenxbio Inc. |
Vectorized lanadelumab and administration thereof
|
WO2022061002A1
(en)
|
2020-09-18 |
2022-03-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Novel adeno-associated viral (aav) vectors to treat hereditary methylmalonic acidemia (mma) caused by methylmalonyl-coa mutase (mmut) deficiency
|
US11401531B2
(en)
|
2020-09-24 |
2022-08-02 |
University Of Massachusetts |
AAV vectors encoding NF1 and uses thereof
|
BR112023003929A2
(pt)
|
2020-10-01 |
2023-04-11 |
Genzyme Corp |
Cassete de expressão de pah humano para tratamento de pku por terapia de reposição gênica direcionada ao fígado
|
AU2021358048A1
(en)
|
2020-10-07 |
2023-05-25 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as high viscosity formulations
|
MX2023003988A
(es)
|
2020-10-07 |
2023-06-22 |
Regenxbio Inc |
Formulaciones para administración supracoroidea tales como formulaciones con formación de agregados.
|
CA3194861A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Formulations for suprachoroidal administration such as gel formulations
|
WO2022076750A2
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns or muscle delivery
|
CA3197342A1
(en)
|
2020-10-07 |
2022-04-14 |
Regenxbio Inc. |
Gene therapy for ocular manifestations of cln2 disease
|
IL301647A
(en)
|
2020-10-07 |
2023-05-01 |
Regenxbio Inc |
Adeno-associated viruses for ocular delivery of gene therapy
|
AU2021356684A1
(en)
|
2020-10-09 |
2023-05-11 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
US11781156B2
(en)
|
2020-10-09 |
2023-10-10 |
Tenaya Therapeutics, Inc. |
Plakophillin-2 gene therapy methods and compositions
|
EP4229186A1
(de)
|
2020-10-18 |
2023-08-23 |
The Trustees of The University of Pennsylvania |
Verbesserter adeno-assoziierter virus (aav)-vektor und verwendungen dafür
|
WO2022094078A1
(en)
|
2020-10-28 |
2022-05-05 |
The Trustees Of The University Of Pennsylvania |
Compositions useful in treatment of rett syndrome
|
MX2023004806A
(es)
|
2020-10-28 |
2023-05-10 |
Regenxbio Inc |
Anticuerpos anti-tnf-a vectorizados para indicaciones oculares.
|
WO2022094157A1
(en)
|
2020-10-28 |
2022-05-05 |
Regenxbio Inc. |
Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
|
EP4236974A2
(de)
|
2020-10-29 |
2023-09-06 |
RegenxBio Inc. |
Vektorisierte faktor xii-antikörper und verabreichung davon
|
JP2023548145A
(ja)
|
2020-10-29 |
2023-11-15 |
リジェネックスバイオ インコーポレイテッド |
眼の適応症に対するベクター化tnf-アルファアンタゴニスト
|
EP4240854A1
(de)
|
2020-11-06 |
2023-09-13 |
Vertex Pharmaceuticals Incorporated |
Zusammensetzungen und verfahren zur behandlung von dm1 mit sclucas9 und sacas9
|
CN112322791B
(zh)
*
|
2020-11-27 |
2023-10-27 |
福建省农业科学院畜牧兽医研究所 |
一种新型鸭依赖属病毒环介导等温扩增检测引物组及试剂盒
|
JP2023551903A
(ja)
|
2020-12-01 |
2023-12-13 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
組織特異的標的化モチーフを有する新規組成物及びそれを含有する組成物
|
US20230414785A1
(en)
|
2020-12-01 |
2023-12-28 |
The Trustees Of The University Of Pennsylvania |
Compositions and uses thereof for treatment of angelman syndrome
|
IL303317A
(en)
|
2020-12-01 |
2023-07-01 |
Akouos Inc |
ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
|
MX2023007315A
(es)
|
2020-12-16 |
2023-08-22 |
Regenxbio Inc |
Método para producir una partícula de virus adenoasociado recombinante.
|
KR20230127263A
(ko)
|
2020-12-29 |
2023-08-31 |
아카우오스, 인크. |
Clrn1-연관된 청력손실 및/또는 시력손실을 치료하기위한 조성물 및 방법
|
WO2022147087A1
(en)
|
2020-12-29 |
2022-07-07 |
Regenxbio Inc. |
Tau-specific antibody gene therapy compositions, methods and uses thereof
|
JP2024503895A
(ja)
|
2021-01-21 |
2024-01-29 |
リジェネクスバイオ インコーポレイテッド |
組換えポリペプチド及びウイルスの生成の改善
|
AU2022212952A1
(en)
|
2021-01-27 |
2023-08-10 |
Umoja Biopharma, Inc. |
Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor
|
AU2022214429A1
(en)
|
2021-02-01 |
2023-09-14 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
WO2022173605A2
(en)
|
2021-02-10 |
2022-08-18 |
Regenxbio Inc. |
Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids)
|
GB202101958D0
(en)
|
2021-02-12 |
2021-03-31 |
Ucl Business Ltd |
Gene therapy for dopamine transporter deficiency syndrome
|
MX2023009978A
(es)
|
2021-02-26 |
2023-09-06 |
Takeda Pharmaceuticals Co |
Composicion y metodos para el tratamiento de la enfermedad de fabry.
|
WO2022182957A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/sacas9
|
WO2022182959A1
(en)
|
2021-02-26 |
2022-09-01 |
Vertex Pharmaceuticals Incorporated |
Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9
|
WO2022187548A1
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
WO2022187473A2
(en)
|
2021-03-03 |
2022-09-09 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
EP4314303A2
(de)
|
2021-03-22 |
2024-02-07 |
Genzyme Corporation |
Grössenausschlusschromatografieanalyse von leeren und vollen aav-kapsiden
|
WO2022204476A1
(en)
|
2021-03-26 |
2022-09-29 |
The Board Of Regents Of The University Of Texas System |
Nucleotide editing to reframe dmd transcripts by base editing and prime editing
|
MX2023012052A
(es)
|
2021-04-12 |
2024-03-15 |
Univ Pennsylvania |
Composiciones útiles para tratar la atrofia muscular espinal y bulbar (sbma).
|
MX2023012513A
(es)
|
2021-04-23 |
2023-12-15 |
Univ Pennsylvania |
Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen.
|
WO2022226296A2
(en)
|
2021-04-23 |
2022-10-27 |
University Of Rochester |
Genome editing by directed non-homologous dna insertion using a retroviral integrase-cas fusion protein and methods of treatment
|
WO2022229851A1
(en)
|
2021-04-26 |
2022-11-03 |
Crispr Therapeutics Ag |
Compositions and methods for using slucas9 scaffold sequences
|
TW202309293A
(zh)
|
2021-04-26 |
2023-03-01 |
美商銳進科斯生物股份有限公司 |
用於治療肌縮蛋白症(dystrophinopathy)之微小肌縮蛋白基因療法給藥
|
EP4334454A2
(de)
|
2021-05-04 |
2024-03-13 |
RegenxBio Inc. |
Neue aav-vektoren sowie verfahren und verwendungen davon
|
WO2022234519A1
(en)
|
2021-05-05 |
2022-11-10 |
Crispr Therapeutics Ag |
Compositions and methods for using sacas9 scaffold sequences
|
WO2022241030A1
(en)
|
2021-05-11 |
2022-11-17 |
Regenxbio Inc. |
Treatment of duchenne muscular dystrophy and combinations thereof
|
JP2024522876A
(ja)
|
2021-06-25 |
2024-06-21 |
オックスフォード バイオメディカ ソリューションズ エルエルシー |
アデノ随伴ウイルスパッケージングシステム
|
JP2024527559A
(ja)
|
2021-07-01 |
2024-07-25 |
インダプタ セラピューティクス インコーポレイテッド |
操作されたナチュラルキラー(nk)細胞及び関連する方法
|
EP4363437A1
(de)
|
2021-07-01 |
2024-05-08 |
Amicus Therapeutics, Inc. |
Neurotensinvarianten und markierte proteine mit neurotensin oder sortilin-propeptid
|
WO2023283649A1
(en)
|
2021-07-08 |
2023-01-12 |
Tenaya Therapeutics, Inc. |
Optimized expression cassettes for gene therapy
|
WO2023004331A1
(en)
|
2021-07-19 |
2023-01-26 |
New York University |
Auf1 combination therapies for treatment of muscle degenerative disease
|
AU2022318664A1
(en)
|
2021-07-30 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
EP4377459A2
(de)
|
2021-07-30 |
2024-06-05 |
Tune Therapeutics, Inc. |
Zusammensetzungen und verfahren zur modulation der expression von frataxin (fxn)
|
WO2023018637A1
(en)
|
2021-08-09 |
2023-02-16 |
Vertex Pharmaceuticals Incorporated |
Gene editing of regulatory elements
|
EP4384544A1
(de)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetisch modifizierte zellen für allogene zelltherapie
|
WO2023019227A1
(en)
|
2021-08-11 |
2023-02-16 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
AU2022325232A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified primary cells for allogeneic cell therapy
|
EP4384193A2
(de)
|
2021-08-11 |
2024-06-19 |
Sana Biotechnology, Inc. |
Genetisch modifizierte zellen für allogene zelltherapie zur reduzierung von durch instant-blut vermittelten entzündungsreaktionen
|
WO2023039444A2
(en)
|
2021-09-08 |
2023-03-16 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
|
KR20240067112A
(ko)
|
2021-09-30 |
2024-05-16 |
아카우오스, 인크. |
Kcnq4-연관 청력손실을 치료하기 위한 조성물 및 방법
|
AR127217A1
(es)
|
2021-10-01 |
2023-12-27 |
Biomarin Pharm Inc |
Tratamiento de angioedema hereditario con vectores de genoterapia de aav y formulaciones terapéuticas
|
WO2023056399A1
(en)
|
2021-10-02 |
2023-04-06 |
The Trustees Of The University Of Pennsylvania |
Novel aav capsids and compositions containing same
|
CN118202060A
(zh)
|
2021-10-05 |
2024-06-14 |
再生生物股份有限公司 |
用于重组aav生产的组合物和方法
|
WO2023060113A1
(en)
|
2021-10-05 |
2023-04-13 |
Regenxbio Inc. |
Compositions and methods for recombinant aav production
|
EP4413019A2
(de)
|
2021-10-07 |
2024-08-14 |
RegenxBio Inc. |
Rekombinante adeno-assoziierte viren zur zns-tropen verabreichung
|
WO2023060269A1
(en)
|
2021-10-07 |
2023-04-13 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for targeted delivery
|
EP4413023A1
(de)
|
2021-10-08 |
2024-08-14 |
SOLA Biosciences LLC |
Zusammensetzungen und verfahren zur behandlung von p53-vermitteltem krebs
|
EP4413024A2
(de)
|
2021-10-08 |
2024-08-14 |
SOLA Biosciences LLC |
Zusammensetzungen und verfahren zur behandlung von proteopathien
|
AU2022371442A1
(en)
|
2021-10-21 |
2024-04-18 |
Vertex Pharmaceuticals Incorporated |
Hypoimmune cells
|
WO2023077092A1
(en)
|
2021-10-28 |
2023-05-04 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2023087019A2
(en)
|
2021-11-15 |
2023-05-19 |
The Trustees Of The University Of Pennsylvania |
Compositions for drg-specific reduction of transgene expression
|
CA3239342A1
(en)
|
2021-11-30 |
2023-06-08 |
Michael Hughes |
Gene therapy methods for treatment of diabetes
|
WO2023102517A1
(en)
|
2021-12-02 |
2023-06-08 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treatment of fabry disease
|
WO2023111348A1
(en)
|
2021-12-17 |
2023-06-22 |
Centre National De La Recherche Scientifique |
Peptides and methods for use in treating pain
|
WO2023125481A1
(zh)
|
2021-12-28 |
2023-07-06 |
成都弘基生物科技有限公司 |
经过修饰的aav衣壳蛋白及其用途
|
TW202338086A
(zh)
|
2022-01-10 |
2023-10-01 |
賓州大學委員會 |
有用於治療異染性白質失養症之組成物
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023133574A1
(en)
|
2022-01-10 |
2023-07-13 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods useful for treatment of c9orf72-mediated disorders
|
WO2023133593A2
(en)
*
|
2022-01-10 |
2023-07-13 |
University Of Florida Research Foundation, Incorporated |
Aav5 capsid variants
|
EP4215614A1
(de)
|
2022-01-24 |
2023-07-26 |
Dynacure |
Kombinationstherapie für dystrophin-verwandte krankheiten
|
AU2023211652A1
(en)
|
2022-01-25 |
2024-08-08 |
The Trustees Of The University Of Pennsylvania |
Aav capsids for improved heart transduction and detargeting of liver
|
TW202342525A
(zh)
|
2022-02-02 |
2023-11-01 |
美商阿科奧斯公司 |
用於治療前庭神經鞘瘤相關症狀之抗vegf抗體構築體及相關方法
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
WO2023154693A1
(en)
|
2022-02-08 |
2023-08-17 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
WO2023156530A1
(en)
|
2022-02-17 |
2023-08-24 |
Lysogene |
Gene therapy for neurodegenerative diseases
|
WO2023172927A1
(en)
|
2022-03-08 |
2023-09-14 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exon 44, 50, and 53 for treatment of duchenne muscular dystrophy
|
WO2023172926A1
(en)
|
2022-03-08 |
2023-09-14 |
Vertex Pharmaceuticals Incorporated |
Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
TW202346590A
(zh)
|
2022-03-13 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
經修飾之肌肉特異性啟動子
|
WO2023183623A1
(en)
|
2022-03-25 |
2023-09-28 |
Regenxbio Inc. |
Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy
|
WO2023187728A1
(en)
|
2022-04-01 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
Gene therapy for diseases with cns manifestations
|
WO2023196851A1
(en)
|
2022-04-06 |
2023-10-12 |
President And Fellows Of Harvard College |
Reversing aging of the central nervous system
|
TW202404651A
(zh)
|
2022-04-06 |
2024-02-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如形成聚集體之調配物
|
WO2023196873A1
(en)
|
2022-04-06 |
2023-10-12 |
Regenxbio Inc. |
Pharmaceutical composition comprising a recombinant adeno-associated virus vector with an expression cassette encoding a transgene forsuprachoidal administration
|
TW202345913A
(zh)
|
2022-04-06 |
2023-12-01 |
美商銳進科斯生物股份有限公司 |
用於脈絡膜上投與之調配物諸如凝膠調配物
|
WO2023196893A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for treating her2 positive metastatic breast cancer and other cancers
|
US20230365968A1
(en)
|
2022-04-06 |
2023-11-16 |
Genzyme Corporation |
Targeted gene therapy for dm-1 myotonic dystrophy
|
WO2023196892A1
(en)
|
2022-04-06 |
2023-10-12 |
The Trustees Of The University Of Pennsylvania |
Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
|
WO2023198652A1
(en)
|
2022-04-11 |
2023-10-19 |
Centre National De La Recherche Scientifique |
Chemically-modified adeno-associated viruses
|
WO2023201207A1
(en)
|
2022-04-11 |
2023-10-19 |
Tenaya Therapeutics, Inc. |
Adeno-associated virus with engineered capsid
|
WO2023198828A1
(en)
|
2022-04-13 |
2023-10-19 |
Universitat Autònoma De Barcelona |
Treatment of neuromuscular diseases via gene therapy that expresses klotho protein
|
WO2023201308A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Gene therapy for treating an ocular disease
|
WO2023201277A1
(en)
|
2022-04-14 |
2023-10-19 |
Regenxbio Inc. |
Recombinant adeno-associated viruses for cns tropic delivery
|
TW202405173A
(zh)
|
2022-04-18 |
2024-02-01 |
美商維泰克斯製藥公司 |
用於增強aav療法及降低aav向肝臟之趨性的組合物及方法
|
WO2023215806A2
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
Vectorized anti-complement antibodies and complement agents and administration thereof
|
WO2023215807A1
(en)
|
2022-05-03 |
2023-11-09 |
Regenxbio Inc. |
VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
|
WO2023214346A1
(en)
|
2022-05-06 |
2023-11-09 |
Novartis Ag |
Novel recombinant aav vp2 fusion polypeptides
|
TW202409064A
(zh)
|
2022-05-25 |
2024-03-01 |
法商塔法吉斯生技公司 |
用於治療疼痛的肽和方法
|
WO2023239627A2
(en)
|
2022-06-08 |
2023-12-14 |
Regenxbio Inc. |
Methods for recombinant aav production
|
WO2023240236A1
(en)
|
2022-06-10 |
2023-12-14 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of spinal muscular atrophy related disorders
|
TW202409289A
(zh)
*
|
2022-06-27 |
2024-03-01 |
美商安斯泰來基因治療股份有限公司 |
用於治療肌強直性營養不良之組合物及方法
|
TW202417467A
(zh)
|
2022-06-28 |
2024-05-01 |
美商航海家醫療公司 |
Aav蛋白殼變異體及其用途
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024011112A1
(en)
|
2022-07-06 |
2024-01-11 |
Voyager Therapeutics, Inc. |
Aav capsid variants and uses thereof
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024020352A1
(en)
|
2022-07-18 |
2024-01-25 |
Vertex Pharmaceuticals Incorporated |
Tandem guide rnas (tg-rnas) and their use in genome editing
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|
WO2024026377A1
(en)
|
2022-07-27 |
2024-02-01 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
CN115354049A
(zh)
*
|
2022-07-29 |
2022-11-18 |
中国科学院深圳先进技术研究院 |
一种基因递送***在将目的基因经静脉注射递送至肝脏的应用
|
WO2024044725A2
(en)
|
2022-08-24 |
2024-02-29 |
Regenxbio Inc. |
Recombinant adeno-associated viruses and uses thereof
|
WO2024042485A1
(en)
|
2022-08-25 |
2024-02-29 |
Takeda Pharmaceutical Company Limited |
Composition for use in the treatment of fabry disease
|
WO2024054983A1
(en)
|
2022-09-08 |
2024-03-14 |
Voyager Therapeutics, Inc. |
Controlled expression of viral proteins
|
TW202417631A
(zh)
|
2022-09-22 |
2024-05-01 |
美商拜奧馬林製藥公司 |
用aav基因治療載體治療心肌病
|
WO2024064863A2
(en)
|
2022-09-22 |
2024-03-28 |
Biomarin Pharmaceutical Inc. |
Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors
|
WO2024073669A1
(en)
|
2022-09-30 |
2024-04-04 |
Regenxbio Inc. |
Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
|
WO2024081746A2
(en)
|
2022-10-11 |
2024-04-18 |
Regenxbio Inc. |
Engineered nucleic acid regulatory elements and methods and uses thereof
|
WO2024105638A1
(en)
|
2022-11-18 |
2024-05-23 |
Jcr Pharmaceuticals Co., Ltd. |
Recombinant aav vectors and methods for treatment of hunter syndrome
|
WO2024130070A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
|
WO2024130067A2
(en)
|
2022-12-17 |
2024-06-20 |
The Trustees Of The University Of Pennsylvania |
Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
|
WO2024134525A1
(en)
|
2022-12-22 |
2024-06-27 |
Fondazione Telethon Ets |
Lsd1 inhibitor and prmt6 inhibitor for use in the treatment of a disease associated with gain-of-function of androgen receptor (ar) and/or with overexpression of an ar coactivator
|
WO2024146935A1
(en)
|
2023-01-06 |
2024-07-11 |
Institut National de la Santé et de la Recherche Médicale |
Intravenous administration of antisense oligonucleotides for the treatment of pain
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
WO2024149844A1
(en)
|
2023-01-12 |
2024-07-18 |
Nantes Université |
Chemically-modified adeno-associated virus
|
CN116622908B
(zh)
*
|
2023-04-13 |
2024-02-06 |
武汉珈创生物技术股份有限公司 |
快速检测野生型腺相关病毒的引物探针、试剂盒及方法和应用
|